secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-086121
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q2 net loss $17.9M; cash $185.5M funds ops into Q1 2024
----------------------------------------------------------------

- Net loss $17.9M in Q2 2022 vs $18.0M in Q2 2021; no revenue reported.
- Cash, equivalents, and marketable securities $185.5M at June 30, down from $219.6M at Dec 31.
- Cash runway expected to fund operations into the first quarter of 2024.
- R&D expenses $12.8M (+$0.9M YoY); G&A expenses $5.3M (-$0.7M YoY).
- Upcoming milestones: NC318 Phase 2 update Q4 2022, NC410/NC762 data H2 2022, NC525 IND filing Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922086121/0001104659-22-086121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922086121/tm2222578d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer